文献速递心脑血管急症重症综合管理与镇静镇痛

孕激素治疗创伤性脑损伤:ProTECT III 试验再分析——基于脑影像分割与生物标志物的客观分类

Progesterone for Traumatic Brain Injury, Experimental Clinical Treatment III Trial Revisited: Objective Classification of Traumatic Brain Injury With Brain Imaging Segmentation and Biomarker Levels.
PubMed 文献 · Crit Care Explor · 2025-09-05
一句话结论在 ProTECT III 再分析中,用 CT 病灶体积分割和 GFAP、UCH-L1 分类中重度 TBI,仍未发现孕激素治疗 24 或 48 小时内的应答亚组。

该研究为 ProTECT III 试验的事后分析,纳入美国 49 家一级创伤中心的中重度创伤性脑损伤(TBI)患者,用脑病灶分析与分割工具(BLASCT)量化 CT 病灶体积,按优化方案将患者分为真阳性与真阴性组,真阳性再按病灶体积分为低(>0.2–10 mL)、中(>10–50 mL)、高(>50 mL)三组。结果显示 GFAP 与 UCH-L1 在低至中等病灶体积的真阳性病例中显著升高;48 小时时仅 UCH-L1 在孕激素组与安慰剂组间有差异;两种标志物与病灶体积均与 Rotterdam 评分相关;未发现性别特异性差异或治疗差异。作者结论认为,尽管分类方法改进,仍未在孕激素治疗 24 或 48 小时内识别出应答亚组,血清标志物与算法化 CT 分析均未优于 Rotterdam 评分或 GCS 等传统指标。

要点

  • 美国 49 家一级创伤中心中重度 TBI 患者中,GFAP 与 UCH-L1 在低至中等病灶体积(>0.2–50 mL)的真阳性病例显著升高。
  • 孕激素组与安慰剂组仅在 48 小时时 UCH-L1 存在差异,GFAP 无差异;未发现性别或治疗差异。
  • 真阳性组两种生物标志物与病灶体积均与 Rotterdam 评分相关。
  • 作者结论:用 CT 分割与血清标志物改进分类后,仍未识别出孕激素治疗 24 或 48 小时内的应答亚组。
  • 作者认为,血清标志物与算法化 CT 分析均未优于 Rotterdam 评分或 GCS 等传统指标,可能需要更严格可量化的损伤性质分类方法。

适用人群与场景

  • 美国 49 家一级创伤中心收治的中重度创伤性脑损伤(TBI)患者,为 ProTECT III 试验的事后分析人群。

诊断标准与关键阈值

  • 用脑病灶分析与分割工具(BLASCT)量化 CT 病灶体积,按优化方案确定阈值使影像学评估与客观病灶体积一致性最大化,据此分为真阳性与真阴性组。
  • 真阳性组再按病灶体积分为低(>0.2–10 mL)、中(>10–50 mL)、高(>50 mL)三组。

研究设计与关键结果

  • 研究类型为 ProTECT III 试验的事后分析,人群为中重度 TBI 患者,设置于美国 49 家一级创伤中心。
  • 干预为孕激素;对照为安慰剂。
  • GFAP 与 UCH-L1 在低至中等病灶体积的真阳性病例中显著升高。
  • 48 小时时仅 UCH-L1 在孕激素组与安慰剂组间存在差异,GFAP 无差异。
  • 真阳性组中两种生物标志物与病灶体积均与 Rotterdam 评分相关。
  • 未发现性别特异性差异或治疗差异。
  • 作者结论:尽管用 CT 影像分割与血清标志物改进了分类,未在孕激素治疗 24 或 48 小时内识别出应答亚组;血清标志物与算法化 CT 分析均未优于 Rotterdam 评分或 GCS 等传统指标。

证据类型、等级与局限

  • 证据类型:ProTECT III 随机对照试验的事后分析。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,血清标志物与算法化 CT 分析在分类 TBI 时均未优于 Rotterdam 评分或 GCS 等传统指标,可能需要更严格可量化的损伤性质分类方法以推动治疗开发。
  • 该再分析未在孕激素治疗 24 或 48 小时内识别出应答亚组,原文未据此给出孕激素用于中重度 TBI 的推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

OBJECTIVE: This post hoc study of the Progesterone for Traumatic Brain Injury, Experimental Clinical Treatment (ProTECT) III trial investigates whether improving traumatic brain injury (TBI) classification, using serum biomarkers (glial fibrillary acidic protein [GFAP] and ubiquitin carboxyl-terminal esterase L1 [UCH-L1]) and algorithmically assessed total lesion volume, could identify a subset of responders to progesterone treatment, beyond broad measures like the Glasgow Coma Scale (GCS) and Glasgow Outcome Scale-Extended (GOS-E), which may fail to capture subtle changes in TBI recovery.

DESIGN: Brain lesion volumes on CT scans were quantified using Brain Lesion Analysis and Segmentation Tool for CT. Patients were classified into true-positive and true-negative groups based on an optimization scheme to determine a threshold that maximizes agreement between radiological assessment and objectively measured lesion volume. True-positives were further categorized into low (> 0.2-10 mL), medium (> 10-50 mL), and high (> 50 mL) lesion volumes for analysis with protein biomarkers and injury severity. Correlation analyses linked Rotterdam scores (RSs) with biomarker levels and lesion volumes, whereas Welch's t-test evaluated biomarker differences between groups and progesterone's effects.

SETTING: Forty-nine level 1 trauma centers in the United States.

PATIENT: Patients with moderate-to-severe TBI.

INTERVENTIONS: Progesterone.

MEASUREMENTS AND MAIN RESULTS: GFAP and UCH-L1 levels were significantly higher in true-positive cases with low to medium lesion volume. Only UCH-L1 differed between progesterone and placebo groups at 48 hours. Both biomarkers and lesion volume in the true-positive group correlated with the RS. No sex-specific or treatment differences were found.

CONCLUSIONS: This study reaffirms elevated levels of GFAP and UCH-L1 as biomarkers for detecting TBI in patients with brain lesions and for predicting clinical outcomes. Despite improved classification using CT-imaging segmentation and serum biomarkers, we did not identify a subset of progesterone responders within 24 or 48 hours of progesterone treatment. More rigorous and quantifiable measures for classifying the nature of injury may be needed to enable development of therapeutics as neither serum markers nor algorithmic CT analysis performed better than the older metrics of Rotterdam or GCS metrics.

来源:Crit Care Explor,查看原文。版权归原作者所有。

参考来源

  1. Cheong S, Gupta R, Kadaba Sridhar S, et al. Progesterone for Traumatic Brain Injury, Experimental Clinical Treatment III Trial Revisited: Objective Classification of Traumatic Brain Injury With Brain Imaging Segmentation and Biomarker Levels. Crit Care Explor. 2025. PMID: 40911759. doi:10.1097/CCE.0000000000001306

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。